CMS Medical Venture Investment
3
17M
2
1
0.33
1
- Areas of investment
Summary
Besides them, we counted 1 critical employee of this fund in our database.
The high activity for fund was in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The increased amount of exits for fund were in 2017.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the CMS Medical Venture Investment, startups are often financed by Juno Capital Partners, Downing Ventures, Downing LLP. The meaningful sponsors for the fund in investment in the same round are Newton Biocapital, Mirae Asset Global Investments, CapDecisif. In the next rounds fund is usually obtained by Newton Biocapital, Go Capital, CapDecisif.
The fund has no exact preference in some founders of portfolio startups. Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Acticor Biotech, Destiny Pharma We can highlight the next thriving fund investment areas, such as Health Care, Biotechnology.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 1
- Exits
- 1
- Follow on index
- 0.33
- Investments by industry
- Pharmaceutical (3)
- Biotechnology (3)
- Biopharma (2)
- Therapeutics (2)
- Health Care (1)
- Investments by region
-
- France (2)
- United Kingdom (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Acticor Biotech | 17 Oct 2018 | Biotechnology, Pharmaceutical, Therapeutics, Biopharma | Early Stage Venture | 18M | Ile-de-France, Paris, France |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.